{"id":"https://openalex.org/W2001737481","doi":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","title":"Fluvoxamine impairs single\u2010dose caffeine clearance without altering caffeine pharmacodynamics","display_name":"Fluvoxamine impairs single\u2010dose caffeine clearance without altering caffeine pharmacodynamics","publication_year":2005,"publication_date":"2005-07-27","ids":{"openalex":"https://openalex.org/W2001737481","doi":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","mag":"2001737481","pmid":"https://pubmed.ncbi.nlm.nih.gov/16236038","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1884944"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.2005.02467.x","doi":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2005.02467.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2005.02467.x","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057983740","display_name":"Kerry Culm-Merdek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerry E. Culm\u2010Merdek","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA","Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]},{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111711726","display_name":"Lisa Lvon Moltke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa L. Von Moltke","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109965072","display_name":"Jerold S. Harmatz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerold S. Harmatz","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087737186","display_name":"David J. Greenblatt","orcid":"https://orcid.org/0000-0003-4719-6226","observed_orcids":["https://orcid.org/0000-0003-4719-6226"]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David J. Greenblatt","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5087737186"],"corresponding_institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":1.0769,"has_fulltext":true,"cited_by_count":59,"citation_normalized_percentile":{"value":0.7647126,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"60","issue":"5","first_page":"486","last_page":"493"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9291999936103821,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9291999936103821,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11264","display_name":"Coffee research and impacts","score":0.07000000029802322,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluvoxamine","display_name":"fluvoxamine","score":1.0},{"id":"https://openalex.org/keywords/caffeine","display_name":"caffeine","score":0.9800000190734863},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9160000085830688},{"id":"https://openalex.org/keywords/cyp1a2-inhibition","display_name":"CYP1A2 inhibition","score":0.9729999899864197},{"id":"https://openalex.org/keywords/caffeine-clearance","display_name":"caffeine clearance","score":0.9739999771118164},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.8830000162124634},{"id":"https://openalex.org/keywords/psychomotor-function","display_name":"psychomotor performance","score":0.8410000205039978},{"id":"https://openalex.org/keywords/eeg-beta-activity","display_name":"EEG beta activity","score":0.7540000081062317},{"id":"https://openalex.org/keywords/central-nervous-system-stimulation","display_name":"central nervous system stimulation","score":0.6980000138282776}],"concepts":[{"id":"https://openalex.org/C2779910183","wikidata":"https://www.wikidata.org/wiki/Q409236","display_name":"Fluvoxamine","level":5,"score":0.9095766544342041},{"id":"https://openalex.org/C2778500429","wikidata":"https://www.wikidata.org/wiki/Q60235","display_name":"Caffeine","level":2,"score":0.8799086809158325},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5836353898048401},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5733716487884521},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5590697526931763},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5061690211296082},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5045133829116821},{"id":"https://openalex.org/C2776814716","wikidata":"https://www.wikidata.org/wiki/Q574801","display_name":"Sedation","level":2,"score":0.4487978219985962},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4354424476623535},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4094061851501465},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28426140546798706},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.08652821183204651},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.07395008206367493},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002110","descriptor_name":"Caffeine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002110","descriptor_name":"Caffeine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002110","descriptor_name":"Caffeine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004569","descriptor_name":"Electroencephalography","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011597","descriptor_name":"Psychomotor Performance","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1365-2125.2005.02467.x","doi":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2005.02467.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1884944","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1884944","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:16236038","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16236038","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2125.2005.02467.x","doi":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2005.02467.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2005.02467.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1096835612","display_name":null,"funder_award_id":"AG-17880","funder_id":"https://openalex.org/F4320337337","funder_display_name":"National Institute on Aging"},{"id":"https://openalex.org/G1298312467","display_name":"GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS","funder_award_id":"R01AT001381","funder_id":"https://openalex.org/F4320337593","funder_display_name":"National Center for Complementary and Integrative Health"},{"id":"https://openalex.org/G1554335716","display_name":null,"funder_award_id":"RA-00054","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G1555653344","display_name":null,"funder_award_id":"DA 13834","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G195712231","display_name":null,"funder_award_id":"MH 58435","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G205198743","display_name":"ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE","funder_award_id":"R21DA013209","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G2266918167","display_name":null,"funder_award_id":"AT01381","funder_id":"https://openalex.org/F4320337593","funder_display_name":"National Center for Complementary and Integrative Health"},{"id":"https://openalex.org/G3859415508","display_name":null,"funder_award_id":"DK-58496","funder_id":"https://openalex.org/F4320337357","funder_display_name":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"id":"https://openalex.org/G4030401367","display_name":"CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY","funder_award_id":"R01DA005258","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G4543083441","display_name":"CYP3A Function in Aging AfricanAmericans","funder_award_id":"R01AG017880","funder_id":"https://openalex.org/F4320337337","funder_display_name":"National Institute on Aging"},{"id":"https://openalex.org/G6814981045","display_name":"REGULATION OF CYTOCHROME P4503A ACTIVITY IN THE ELDERLY","funder_award_id":"R01MH058435","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G7494422097","display_name":"HAART Regimens in Substance Abusers","funder_award_id":"R01DA013834","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G763268302","display_name":null,"funder_award_id":"DA 13209","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G806220931","display_name":null,"funder_award_id":"DA05258","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G8862829772","display_name":"Metabolic Consequences of HAART: CYP3A and P-gp","funder_award_id":"R01DK058496","funder_id":"https://openalex.org/F4320337357","funder_display_name":"National Institute of Diabetes and Digestive and Kidney Diseases"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337337","display_name":"National Institute on Aging","ror":"https://ror.org/049v75w11"},{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"},{"id":"https://openalex.org/F4320337357","display_name":"National Institute of Diabetes and Digestive and Kidney Diseases","ror":"https://ror.org/00adh9b73"},{"id":"https://openalex.org/F4320337593","display_name":"National Center for Complementary and Integrative Health","ror":"https://ror.org/00190t495"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2001737481.pdf","grobid_xml":"https://content.openalex.org/works/W2001737481.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1762007948","https://openalex.org/W1846398386","https://openalex.org/W1868596321","https://openalex.org/W1868748626","https://openalex.org/W1903003882","https://openalex.org/W1946647386","https://openalex.org/W1969652902","https://openalex.org/W1972130003","https://openalex.org/W1972280475","https://openalex.org/W1980433856","https://openalex.org/W1985300130","https://openalex.org/W1986838867","https://openalex.org/W2003197532","https://openalex.org/W2023580320","https://openalex.org/W2027692702","https://openalex.org/W2032290269","https://openalex.org/W2035555993","https://openalex.org/W2042061501","https://openalex.org/W2045008930","https://openalex.org/W2046107045","https://openalex.org/W2050450820","https://openalex.org/W2050561574","https://openalex.org/W2052085254","https://openalex.org/W2054377010","https://openalex.org/W2060907139","https://openalex.org/W2066312456","https://openalex.org/W2073995720","https://openalex.org/W2076127970","https://openalex.org/W2080293954","https://openalex.org/W2080496807","https://openalex.org/W2097502628","https://openalex.org/W2131020156","https://openalex.org/W2162252433","https://openalex.org/W4206247212"],"related_works":["https://openalex.org/W2063213551","https://openalex.org/W2034889895","https://openalex.org/W2046107045","https://openalex.org/W2003197532","https://openalex.org/W4244973830","https://openalex.org/W2070644309","https://openalex.org/W2094555978","https://openalex.org/W2023580320","https://openalex.org/W2161587482","https://openalex.org/W1969294497"],"abstract_inverted_index":{"BACKGROUND:":[0],"Coadministration":[1],"of":[2,7,19,26,37,44,47,58,68,118,177,206],"fluvoxamine":[3,38,65,95],"impairs":[4],"the":[5,35,40],"clearance":[6,117],"caffeine":[8,59,88,93,119,171,183,190,207],"and":[9,42,94,102,136],"prolongs":[10],"its":[11,138],"elimination":[12,139],"half-life,":[13],"which":[14],"is":[15,29],"attributable":[16,169],"to":[17,170,203],"inhibition":[18],"CYP1A2":[20],"by":[21,175],"fluvoxamine.":[22,178],"The":[23],"clinical":[24],"importance":[25],"this":[27,193],"interaction":[28],"not":[30,173,196],"established.":[31],"AIM:":[32],"To":[33],"evaluate":[34],"effects":[36,158,168,201],"on":[39],"kinetics":[41],"dynamics":[43],"single":[45,54],"doses":[46,57,67],"caffeine.":[48],"METHODS:":[49],"Seven":[50],"healthy":[51],"subjects":[52],"received":[53],"250":[55],"mg":[56,70],"(or":[60],"matching":[61,76],"placebo)":[62],"together":[63],"with":[64,75,160,208],"(four":[66],"100":[69],"over":[71],"2":[72],"days)":[73],"or":[74,89,166],"placebo":[77,90],"in":[78,189,211],"a":[79],"double-blind,":[80],"four-way":[81],"crossover":[82],"study.":[83],"For":[84],"24":[85],"h":[86],"after":[87],"administration,":[91],"plasma":[92],"concentrations":[96],"were":[97,108,172],"determined.":[98],"Psychomotor":[99],"performance,":[100,164],"sedation,":[101],"electroencephalographic":[103],"(EEG)":[104],"\"beta\"":[105],"frequency":[106],"activity":[107],"also":[109],"assessed.":[110],"RESULTS:":[111],"Fluvoxamine":[112,180],"significantly":[113],"reduced":[114],"apparent":[115],"oral":[116],"(105":[120],"vs.":[121,142],"9.1":[122],"mL":[123,131],"min(-1),":[124,132],"P":[125,145],"<":[126,146],"0.01;":[127,147],"mean":[128,148],"difference:":[129,149],"95.7":[130],"95%":[133,152],"CI:":[134,153],"54.9-135.6),":[135],"prolonged":[137],"half-life":[140],"(4.9":[141],"56":[143],"h,":[144,151],"51":[150],"26-76).":[154],"Caffeine":[155],"produced":[156],"CNS-stimulating":[157],"compared":[159],"placebo.":[161],"However,":[162,192],"psychomotor":[163],"alertness,":[165],"EEG":[167],"augmented":[174],"coadministration":[176],"CONCLUSIONS:":[179],"greatly":[181],"impaired":[182],"clearance,":[184],"but":[185],"without":[186],"detectable":[187],"changes":[188],"pharmacodynamics.":[191],"study":[194],"does":[195],"rule":[197],"out":[198],"possible":[199],"adverse":[200],"due":[202],"extensive":[204],"accumulation":[205],"daily":[209],"ingestion":[210],"fluvoxamine-treated":[212],"individuals.":[213]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}